skip to Main Content

FDA Grants Orphan Drug Designation to Zenocutuzumab as Treatment of Pancreatic Cancer

The FDA has granted an Orphan Drug designation to zenocutuzumab (MCLA-128) for the treatment of patients with pancreatic cancer, announced Merus in a press release.

“Receiving Orphan Drug designation for zenocutuzumab is another important milestone for our lead program, and it validates the significant unmet need in patients with pancreatic cancer,” said Bill Lundberg, MD, president, chief executive officer and principal financial officer of Merus, in a statement. “We are pleased with the progress we are making in our ongoing global clinical trial and believe that zenocutuzumab has the potential to play a significant role in shifting the treatment paradigm for NRG1 fusion cancers from conventional chemotherapy to a personalized medicine approach.” Read more . . . 

 


Back To Top